The Skinny on GLP-1 Meds

GLP-1/GIP Medications for Weight Management: What You Need to Know

You've seen the headlines. You've heard the whispers. Maybe you've even watched your favorite celebrity shrink before your eyes on Instagram. GLP-1 and GIP medications are everywhere, and everyone's got an opinion.

But here's the thing—between the TikTok doctors, the pharma ads, and your aunt who suddenly became a medical expert after reading one WebMD article, it's hard to know what's actually true about these weight loss medications.

What Are These Medications?

GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) medications were originally developed for diabetes management. They work by mimicking hormones that regulate blood sugar, slow stomach emptying, and tell your brain you're full even when you've eaten less.

The weight loss effect was initially considered a "side benefit" for diabetic patients, but pharmaceutical companies quickly realized they had struck gold. Now these medications are FDA-approved for weight management, and they're changing the game in ways we haven't seen since, well... ever.

Research published in JAMA Internal Medicine shows these medications produce significant results—patients losing 15-20% of their body weight in clinical trials. For someone starting at 200 pounds, that's 30-40 pounds, substantially more effective than most traditional approaches.

Medication Options

Brand Name Medications

Semaglutide (Ozempic® and Wegovy®)

• Same active ingredient with different FDA approvals (Ozempic for diabetes, Wegovy for weight management)

• Come in autoinjector pens

• Clinical trials show average weight loss of 15% over 68 weeks

Tirzepatide (Mounjaro® and Zepbound®)

• Same active ingredient with different FDA approvals (Mounjaro for diabetes, Zepbound for weight management)

• Come in autoinjector pens

• Clinical trials show average weight loss of 20.9%

Zepbound® Vials

• Same medication as Zepbound pens but in vial form requiring separate syringes

• More affordable for self-pay patients (approximately $499/month vs. $1,000+)

Compounded Medications

Compounded versions are prepared by specialized pharmacies following FDA regulations. They may be appropriate for patients who:

• Have allergies to inactive ingredients in brand-name versions

• Need specific dosages not commercially available

• Want to avoid supply shortages affecting brand-name products

Cost Considerations

With Insurance:

• $25-$100 per month if covered

• Coverage often limited to diabetes treatment or requires specific BMI thresholds and documentation of previous weight loss attempts

Without Insurance:

• Brand-name pens: $1,000-$1,300 per month

• Zepbound vials: $499 per month through Lilly's Self-Pay program

• Compounded versions: $200-$400 per month

Manufacturer savings cards can help reduce costs but typically have limitations and expiration dates.

What It's Actually Like to Take These Meds

Most people experience:

• Reduced hunger and fewer cravings

• Earlier feeling of fullness when eating

• Decreased interest in food, particularly high-fat or sweet foods

• Better recognition of true hunger versus emotional eating

Adjustment Period

Common initial effects that typically improve over time:

• Nausea, particularly after eating too much or too quickly

• Changes in bowel movements

• Potential acid reflux or heartburn

• Initial fatigue

Healthcare providers typically start with lower doses and gradually increase them to minimize these effects.

Typical Results Timeline

• First few weeks: Adjustment to medication, beginning of appetite changes

• 1-4 months: Noticeable weight loss begins (typically 2-3% per month)

• 4-10 months: Continued steady weight loss with proper nutrition and lifestyle

• 10+ months: Approaching maximum results (most reach peak weight loss between 10-12 months)

Beyond Weight Loss

GLP-1/GIP medications aren't magic pills, and they're not right for everyone. They're tools—powerful ones, but still just tools. They work best when combined with:

• Regular medical monitoring through lab work and check-ups

• Nutritional guidance tailored to work with the medication's effects

• Appropriate physical activity

• Stress management and adequate sleep

These medications can be used long-term, but they’re not always necessary forever. Patients have options:

• Continuing at a therapeutic dose

• Transitioning to a lower maintenance dose

• Gradually tapering off while maintaining lifestyle changes

• Using the medication intermittently as needed

Who Should Consider These Medications

Potential Candidates

• People with BMI over 30, or over 27 with weight-related health conditions

• Those who have tried multiple diet and exercise programs without success

• Individuals looking to break the cycle of yo-yo dieting

• People needing weight loss before medical procedures

• Those addressing weight gain related to life changes

• Individuals with conditions like PCOS and other metabolic syndromes

Not Appropriate For

• People with history of pancreatitis

• Those with personal or family history of medullary thyroid carcinoma

• People with multiple endocrine neoplasia syndrome type 2

• Pregnant or breastfeeding individuals

• Those with serious kidney or liver issues

• People with history of gastroparesis

Weight Wellness: Beyond Just Losing Pounds

Ready to take control of your health in a way that actually lasts? If you’re done with guesswork and fad fixes, now’s the time to see what a data-driven approach with GLP-1/GIP therapy can do for you.

Schedule a no-pressure consultation with one of our providers to review your goals, dive into your lab results, and map out a plan that fits your life. Trust us—your future self will breathe a little easier knowing you started today.

‍

‍

‍

References

1. Journal of the American Medical Association Internal Medicine. "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity." https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080

2. New England Journal of Medicine. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

3. Eli Lilly Investor Relations. "Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head SURMOUNT-5 obesity trial." https://investor.lilly.com/news-releases/news-release-details/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head

4. FDA. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

5. International Journal of Obesity. "Maintaining weight loss achieved with GLP-1 receptor agonists: a narrative review." https://www.nature.com/articles/s41366-023-01325-1

‍